SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Venus Remedies shines on registering with DSIR to avail custom duty exemption

14 Sep 2023 Evaluate

Venus Remedies is currently trading at Rs. 243.10, up by 11.35 points or 4.90% from its previous closing of Rs. 231.75 on the BSE.

The scrip opened at Rs. 240.00 and has touched a high and low of Rs. 243.30 and Rs. 232.50 respectively. So far 6083 shares were traded on the counter.

The BSE group 'T' stock of face value Rs. 10 has touched a 52 week high of Rs. 301.80 on 10-Jul-2023 and a 52 week low of Rs. 145.00 on 08-Feb-2023.

Last one week high and low of the scrip stood at Rs. 246.00 and Rs. 226.15 respectively. The current market cap of the company is Rs. 316.93 crore.

The promoters holding in the company stood at 41.76%, while Institutions and Non-Institutions held 0.98% and 57.26% respectively.

Venus Remedies has made registration with Department of Scientific and Industrial Research (DSIR), Ministry of Science & Technology, Government of India. This significant milestone allows the company to avail custom duty exemption, reinforcing its commitment to innovation, excellence in research, and its substantial contributions to the healthcare sector.

This registration with DSIR exemplifies Venus Remedies' dedication to fostering innovation and making healthcare solutions more accessible. With a strong track record of brining 15 patented products to market and a robust pipeline of innovative pharmaceuticals, the company has consistently demonstrated a forward-thinking approach to drug development.

Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.

Venus Remedies Share Price

998.60 -52.55 (-5.00%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×